High incidence of discontinuations due to adverse events in patients treated with ceftaroline

Pharmacotherapy

Volumn 34, Issue 7, 2014, Pages 758-763

  Jain, Rupali ^a,b   Chan, Jeannie D ^b,c   Rogers, Lisa ^a   Dellit, Timothy H ^c,d   Lynch, John B ^c,d   Pottinger, Paul S ^a,d  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

adverse events; ceftaroline; hematologic toxicities; methicillin resistant Staphylococcus aureus; rash

Indexed keywords

CEFTAROLINE; CEPHALOSPORIN DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMORBIDITY; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HUMAN; INCIDENCE; MACULOPAPULAR RASH; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIDDLE AGED; NEUTROPENIA; OFF LABEL DRUG USE; RASH; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; VERY ELDERLY; CHEMICALLY INDUCED; HEMATOLOGIC DISEASES; INTRAVENOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; CEPHALOSPORINS; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84903849000     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1435     Document Type: Article

References (18)

1. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community acquired pneumonia. Clin Infect Dis 2010; 51: 1395-405.
2. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: 641-50.
3. Rank D, Friedland DH, Laudano JB,. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (suppl 3): iii53-9.
4. Rose WE, Schulz LT, Andes D, et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012; 56: 5296-302.
5. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS,. Methicllin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012; 67: 1267-70.
6. Jongsma K, Joson J, Heidari A,. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report. J Antimicrob Chemother 2013; 68: 1444-5.
7. Zainah H, Hammoud M, Vazquez JA,. Use of ceftaroline in the management of vertebral osteomyelitis. Infect Dis Clin Pract 2013; 21: 269-71.
8. Najjar S, Biehle L, Najjar J, Finkel DG,. Treatment of methicillin-resistant Staphylococcus aureus bacteremia and prosthetic valve endocarditis with ceftaroline. Infect Dis Clin Pract 2014; 22: 108-9.
9. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J,. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 2013; 19: 42-9.
10. Polenakovik HM, Pleiman CM,. Ceftaroline for methicillin-resistant Staphylococcus aureus bacteremia: case series and review of the literature. Int J Antimicrob Agents 2013; 42: 450-5.
11. Rimawi R, Frenkel A, Cook PP,. Ceftaroline-a cause for neutropenia. J Clin Pharm Ther 2013; 38: 330-2.
12. U.S. Food and Drug Administration. Teflaro Prescribing Information. Available from http://www.frx.com/pi/teflaro-pi.pdf. Accessed February 7th 2014.
13. Lai M, Rosner F, Ritz ND,. Hemolytic anemia due to antibodies to penicillin. JAMA 1966; 198: 483-4.
14. Seltsam A, Salama A,. Ceftriaxone-induced immune hemolysis: two case reports and a concise review of the literature. Intensive Care Med 2000; 26: 1390-4.
15. Olaison L, Belin L, Hogevik H, Alestig K,. Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis. Arch Intern Med 1999; 159: 607-15.
16. Whitman CB, Joseph JM, Sjoholm L,. Cephalosporin-induced leukopenia following rechallenge with cefoxitin. Ann Pharmacother 2008; 42: 1327-32.
17. Peralta FG, Sanchez MB, Roiz MP, et al. Incidence of neutropenia during treatment of bone-related infections with piperacilin-tazobactam. Clin Infect Dis 2003; 37: 1568-72.
18. Olaison L, Alestig K,. A prospective study of neutropenia induced by high doses of beta-lactam antibiotics. J Antimicrob Chemother 1990; 30: 239-45.